Notably, API markedly reduced the phosphorylation of PI3K and AKT (p < 0.001, p < 0.0001, α = 0.05), suggesting an inhibition of PI3K/AKT activation, while concurrently increasing the expression of p53 (p < 0.01, α = 0.05), potentially restoring p53-mediated tumor suppression mechanisms (Ghosh et al., 2023; Yang et al., 2023; Nakagawa-Saito et al., 2024). The gene discussed is TP53; the disease is neoplasm.